UBS Maintains Buy on Boston Scientific, Raises Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Danielle Antalffy maintains a Buy rating on Boston Scientific (BSX) and raises the price target from $74 to $90.
April 25, 2024 | 2:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS analyst Danielle Antalffy maintains a Buy rating on Boston Scientific and raises the price target from $74 to $90.
The increase in price target by a reputable analyst like Danielle Antalffy from UBS is a strong positive signal for Boston Scientific. It suggests confidence in the company's future performance and growth prospects, likely leading to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100